Research Project Title |
Acronym |
Data controler |
Lawfulness of processing |
Recipients of the data |
Data retention period |
Category of data |
Transfer outside the EU |
Association between depressive and anxious symptoms and morbidity after surgery in esogastric cancer patients |
DAMCHIR / ANDEMOCHIR |
Lille university, CNRS UMR 9193 |
Public interest |
Academic |
Completion of research |
Clinical data - Questionnaires |
No |
Effect of patients' perceived medical empathy and emotional competence on their adjustment to cancer |
CEMA |
Lille university, CNRS UMR 9193 |
Public interest |
Academic |
Completion of research |
Clinical data - Questionnaires |
No |
Establishment of functional molecular signatures of gastroesophageal junction (GEJ) adenocarcinomas and role in treatment response |
EASTMAN |
Lille university, CNRS UMR 8161 |
Public interest |
Academic |
Completion of research |
Clinical data –Tumours samples |
No |
Impact of patient-physician emotional regulation on the patient's medical outcome |
EMOVOL |
Lille university, CNRS UMR 9193 |
Public interest |
Academic |
Completion of research |
Clinical data - Questionnaires |
No |
Stomach Genome Wide Association Studies |
GWAS stomach |
CHU de Lille |
Public interest |
Academic |
Completion of research |
Clinical data –blood samples |
No |
Role of socioeconomic and environmental inequalities on esogastric cancers |
INEKOG |
Lille university, UMR CNRS 9221 |
Public interest |
Academic |
Completion of research |
Clinical data - Questionnaires |
No |
Post esophagectomy mortality root cause analysis |
PEMRCA |
AP-HP |
Public interest |
Academic |
Completion of research |
Clinical data |
No |
Molecular profiling of esogastric adenocarcinoma recurrences |
PROMOREC |
CHU de Lille |
Public interest |
Academic |
Completion of research |
Clinical data –Tumours samples |
No |
Identification of therapeutic targets of recurrent gastric cell carcinoma by very high-throughput sequencing |
REComics |
CHU de Lille |
Public interest |
Academic |
Completion of research |
Clinical data –Tumours samples |
No |
Impact of FDG PET after neoadjuvant radiochemotherapy in esophageal cancer patients: value of follow-up? |
TEP-oeso-RCT |
CHU de Lille |
Public interest |
Academic |
Completion of research |
Clinical data |
No |
Value of histologic response to preoperative chemotherapy in predicting the efficacy of postoperative chemotherapy in gastric adenocarcinoma |
TRG |
CHU de Lille |
Public interest |
Academic |
Completion of research |
Clinical data |
No |
Assessment and emotional determinants of health-related quality of life deterioration in patients with esogastric cancer |
DETAVIE |
CHU de Besançon |
Public interest |
Academic |
Completion of research |
Clinical data - Questionnaires |
No |
Understanding the molecular mechanisms associated with tumor resistance in gastric adenocarcinoma |
miniPRESTO |
Institut régional du cancer de Montpellier |
Public interest |
Academic |
Completion of research |
Clinical data –Tumours samples |
No |
Biological analyses and response to therapy of esogastric adenocarcinomas with microsatellite instability |
ARTEMSI |
CHU de Lille |
Public interest |
Academic |
Completion of research |
Clinical data –Tumours samples |
No |
MS Guide surgery for gastric cancer |
MS Guide |
Lille university, INSERM U1192 |
Public interest |
Academic |
Completion of research |
Clinical data –Tumours samples |
No |
Development of a statistical model for the prediction of MSI status from digitized H&E slides of tumor tissue |
MSI-IA |
CHU de Lille |
Public interest |
Academic |
Completion of research |
Clinical data –Tumours samples |
No |
Using artificial intelligence to predict the molecular subtype and oncologic outcome of patients with adenocarcinoma of the stomach |
FREGANET |
CHU de Lille |
Public interest |
Academic |
Completion of research |
Clinical data –Tumours samples |
No |
Using artificial intelligence to predict the molecular subtype and oncologic outcome of patients with esophageal adenocarcinoma |
FREGATIA |
CHU de Lille |
Public interest |
Academic |
Completion of research |
Clinical data –Tumours samples |
No |
Assessment of the predictive value of plasma proteins in oesophageal adenocarcinoma treatment |
ASPECT |
St Andrews University (Scotland) |
Public interest |
Academic |
Completion of research |
Clinical data –blood samples |
No |
Identification of rare and penetrating germline mutations and genes for gastric cancer, diagnosed before age 50 |
WES stomach |
University Hospital of Marburg, Center for Human genetics (Germany) |
Public interest |
Academic |
Completion of research |
Clinical data –blood samples |
No |
2019-01 |
2019-01 |
Industrial |
Public interest |
Industrial |
Completion of research |
Clinical data |
No |
2020-01 |
2020-01 |
Industrial |
Public interest |
Industrial |
Completion of research |
Clinical data |
No |
nOde Metastasis EsoGastric cAncer |
OMEGA | Association pour l’étude des maladies digestives | Public interest | Academic | Completion of research | Clinical data | No |
Effects of centralization of cancer care on patients' quality of life. Analysis and perspectives from the FREGAT cohort (oesogastric cancers). | CENTRAVIE | Centre Léon Bérard | Public interest | Academic | Completion of research | Clinical data - Questionnaires | No |
Disease burden, epidemiology, treatment patterns and healthcare resource utilization in France for locally advanced unresectable or metastatic adenocarcinoma of gastric and gastroesophageal Junction (G/GEJ): an analysis using the FREnch EsoGAstric Tumours (FREGAT) Database | BECOME | Astellas | Public interest | Industrial | Completion of research | Clinical data | No |
Feasibility and efficacy of perioperative treatment in patients over 75 years managed for localized adenocarcinoma of the stomach or GEJ. | STOMAGE | CHU de Lille | Public interest | Academic | Completion of research | Clinical data | No |
Defining Predictive Immunedeterminants of response to neoadjuvant Chemoradiation in Oesophageal adenocarcinoma. |
PREDICO |
San Raffaele Scientific Institute (Italy) |
Public interest |
Academic |
Completion of research |
Clinical data –Tumours and blood samples |
No |
Dissecting metabolic hetergoneity in oesophageal cancer to increase immunotherapy afficacy and overcome resistance |
IMPROVE |
Institut Pasteur Lille |
Public interest |
Academic |
Completion of research |
Clinical data –Tumours |
No |
Real world management and outcomes of patients with non-metastatic esophageal squamous cell carcinoma in the FREGAT database |
2024-01 |
CHU de Lille |
Public interest |
Academic |
Completion of research |
Clinical data |
No |
Determination of microbiological factors predictive of response to neoadjuvant therapy in non-metastatic esophageal adenocarcinoma nd esogastric junction |
MICADOE |
CHU de Lille |
Public interest |
Academic |
Completion of research |
Clinical data |
No |
Impact of the COVID-19 pandemic on the stage at diagnosis, treatment and prognosis of patients with esogastric cancer in the FREGAT cohort |
CAGOCOVID |
CHU de Reims |
Public interest |
Academic |
Completion of research |
Clinical data |
No |
Real-life patient pathway for the management of resectable gastric cancer or cancer of the gastro-oesophageal junction. Retrospective observational study based on secondary data from the FREGAT database. |
ARAVIS |
Laboratoire AstraZeneca |
Public interest |
Industrial | Completion of research | Clinical data |
No |
Assessment of the value of postoperative chemotherapy in gastric adenocarcinoma operated on with a significant pathological response after pre-operative chemotherapy: a French retrospective real-life comparative study from the FREGAT group |
STARGATE-1 |
Nancy university hospital |
Public interest |
Academic |
Completion of research |
Clinical data |
No |
A retrospective cohort study to assess the prevalence of FGFR2b overexpression, biomarkers overlap, patient characteristics and treatment outcomes by FGFR2b status among patients with locally advanced unresectable or metastatic gastric or gastroesophageal junction cancer in the FREGAT database in France (Beluga study) |
BELUGA |
AMGEN |
Public interest |
Industrial |
Completion of research |
Clinical data - Tumours samples |
No |